A Case Crossover Study of Intermittent Fasting in CLL/SLL
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
About this trial
This is an interventional prevention trial for Chronic Lymphocytic Leukemia (CLL) focused on measuring diet, nutrition, intermittent fasting, time restricted feeding, oncology, autophagy, metabolomics
Eligibility Criteria
Inclusion Criteria: Diagnosis of CLL or SLL Age < 85 years Peripheral blood lymphocytes >20 x 109/L Hemoglobin > 90g/L Platelets > 90 x 10*9/L BMI of >=20kg/m2 ECOG Performance Status >=2 Completion of "IF in CLL/SLL Study" (ClinicalTrials.gov Identifier: NCT04626843) followed by minimum of 3 month ad libitum eating Exclusion Criteria: Patient unable to give consent Patient on medications required to be taken with food during the fasting window Pregnancy Diabetes mellitus BMI drop to < 18.5kg/m2 at any time during study Anti-lymphoma therapy within the past 3 months Expected to require initiation of anti-lymphoma therapy within the next 3 months
Sites / Locations
- Eleah Stringer
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
5:2 Method
16/8 Method
Participants will follow the 5:2 Method (an intermittent fasting regimen) for a 90 day duration. This entails eating ad libitum for five days per week ("normal days") and limiting total calorie intake to 800kcals per day ("fasting days") for the remaining two days per week. The fasting days can be sequential or dispersed throughout the week, based on patient preference.
Participants will have already followed the 16/8 Method (an intermittent fasting regimen) for a minimum of six days per week for a 90 day duration. This entailed limiting the eating hours to an 8-hour window, then fasting for the remaining 16 hours per day, with the last time of intake being 8pm.